血塞通胶囊联合尼麦角林治疗前循环急性缺血性脑卒中患者的疗效

doi:10.3969/j.issn.1671-7171.2026.05.026

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1095 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of Xuesaitong Capsules combined with nicergoline in patients with anterior circulation acute ischemic stroke (AIS). 【Methods】 A total of 100 patients with anterior circulation AIS treated in our hospitals from August 2021 to August 2023 were randomly divided into a Xuesaitong group and a combination group, with 50 patients in each group. The Xuesaitong group was treated with Xuesaitong Capsules alone, while the combination group was treated with combination of Xuesaitong Capsules and nicergoline. Clinical efficacy, cognitive function [Mini-Mental State Examination (MMSE) score], neurological function [National Institutes of Health Stroke Scale (NIHSS) score], activities of daily living [Barthel Index (BI) score], and safety were compared between the two groups before and after treatment. 【Results】 The total effective rate in the combination group was higher than that in the Xuesaitong group (P<0.05). After treatment, MMSE and BI scores in the combination group were higher than those in the Xuesaitong group, while NIHSS scores of the combination group were lower than that of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Xuesaitong Capsules combined with nicergoline show significant efficacy in the treatment of anterior circulation AIS, improving cognitive function, neurological function, and activities of daily living, with good safety.

Key words： Ischemic Stroke Nicergoline Chinese Patent Drugs Treatment Outcome

Received: 11 August 2025

PACS:

R743.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Ming
	LI Dong
	LIU Jinhui

Cite this article:

WANG Ming,LI Dong,LIU Jinhui. Efficacy of Xuesaitong Capsules Combined with Nicergoline in Patients with Anterior Circulation Acute Ischemic Stroke[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(5): 799-801.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.05.026 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I5/799

[1] 蔺茹月,范建强,王丽君,等. 甘油三酯-葡萄糖指数与前循环大血管闭塞急性缺血性脑卒中的关系[J].海军军医大学学报,2025,46(4):435-441.
[2] 邓鹏飞,冯伟明,黄炜超. 血管内治疗发病时间＞24 h前循环大血管闭塞性急性缺血性脑卒中的疗效分析[J].卒中与神经疾病,2025,32(3):281-284.
[3] 李娇,山彩霞,曹飞,等. 血塞通联合阿加曲班治疗急性脑梗死的临床效果观察[J].神经疾病与精神卫生,2025,25(1):57-61.
[4] 赵卫丽,刘雅林,张茜,等. 替奈普酶联合尼麦角林治疗缺血性脑卒中患者的疗效及安全性[J].中国药物应用与监测,2025,22(2):311-314.
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[6] 汪凯,董强. 卒中后认知障碍管理专家共识2021[J].中国卒中杂志,2021,16(4):376-389.
[7] 张虎,第五永长,杨谦,等. 中老年轻度认知功能障碍患者中医证候要素与MMSE及MoCA量表评分相关性研究[J].中华中医药杂志,2024,39(4):2021-2026.
[8] 邹瑜聪,林炜明,周静,等. 非医疗专业护工使用Barthel指数评估脑卒中患者日常生活活动能力的可行性分析[J].中国医药导报,2024,21(13):120-124.
[9] 宋庆云,吴文娟,刘小娟,等. Hcy与sTWEAK对前循环急性缺血性脑卒中患者脑白质病变的评估价值[J].中国实用神经疾病杂志,2025,28(3):326-330.
[10] 张洋,陈莎,陈彤,等. 基于侧支循环评分及临床特征构建急性前循环缺血性脑卒中机械取栓预后列线图预测模型[J].徐州医科大学学报,2025,45(5):339-345.
[11] 刘珊,闵玺,胡淑国,等. 血塞通联合丁苯酞对2型糖尿病合并脑梗死的疗效分析[J].河北医药,2023,45(5):722-725.
[12] 王静,刘学春,张德智,等. 尼麦角林联合高压氧治疗对急性缺血性脑卒中患者神经功能和血清因子的影响[J].创伤与急危重病医学,2025,13(1):38-42.
[13] 李备,吉四辈,刘俊丽,等. 血清IGF-1与cGP在急性缺血性脑卒中患者中的预后评估价值[J].神经疾病与精神卫生,2025,25(6):402-408.
[14] 焦腾飞,肖书玲,杨晶,等. NIHSS评分及肺部感染预测缺血性脑卒中晚期癫痫发作的价值评估[J].脑与神经疾病杂志,2024,32(8):518-522.